Cost-effectiveness of an outreach program for HCC screening in patients with cirrhosis: a microsimulation modeling study

被引:0
|
作者
Gurley, Tami [1 ]
Hernaez, Ruben [2 ,3 ]
Cerda, Vanessa [1 ]
Thomas, Tynaje [1 ]
Narasimman, Manasa [4 ]
Mittal, Sukul [4 ]
Al-Hasan, Mohammed [4 ]
Daher, Darine [4 ]
Singal, Amit G. [4 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Donnell Sch Publ Hlth, Dallas, TX USA
[2] Michael E DeBakey VA Med Ctr, Dept Med, Houston, TX USA
[3] Baylor Coll Med, Houston, TX USA
[4] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA
关键词
Liver cancer; Screening; Ultrasound; Outreach; Interventions; HEPATOCELLULAR-CARCINOMA SURVEILLANCE; DECOMPENSATED CIRRHOSIS; ASSOCIATION; OUTCOMES; QUALITY; DISEASE; LIFE;
D O I
10.1016/j.eclinm.2025.103113
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Patients with cirrhosis are at high risk for hepatocellular carcinoma (HCC), but few undergo guideline- recommended semi-annual screening. Randomized clinical trials (RCTs) demonstrate that mailed outreach can increase screening versus visit-based screening. We estimated the costs and cost-effectiveness of an outreach strategy versus usual care. Methods We built a 10-year Markov chain Monte Carlo microsimulation model to conduct a cost-effectiveness analysis comparing a mailed outreach program versus usual care for HCC screening in a cohort of 10,000 patients with cirrhosis. Model inputs were based on literature review (2005-current), and costs were based on inflation-adjusted estimates from Surveillance, Epidemiology, and End Results (SEER)-Medicare claims data. We conducted one-way sensitivity analyses for HCC incidence, outreach costs, efficacy of the outreach strategy to increase screening, and efficacy of curative (versus palliative) HCC treatments. Findings Mailed outreach was estimated to cost $32.45 per patient in the first year and $21.90 per patient in subsequent years. The outreach program increased the number of HCC patients detected at an early stage by 48.4% and increased quality-adjusted life years (QALYs) by 300. Cost savings from these increases offset the costs of mailed outreach. Mailed outreach remained cost-effective across a wide range of HCC incidence rates, outreach costs, efficacy of the outreach strategy to increase screening, and the efficacy of curative HCC treatments. Annual out-ofpocket patient costs in the outreach arm were low at $13 per year. Interpretation Mailed outreach to encourage HCC screening in patients with cirrhosis dominates usual care and should be considered for implementation in routine practice. Funding National Cancer Institute and Cancer Prevention Research Institute of Texas. Copyright (c) 2025 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页数:9
相关论文
共 50 条
  • [11] A cost-effectiveness analysis of screening for hepatocellular carcinoma (HCC) in hepatitis C-related compensated cirrhosis.
    Dube, C
    Nichol, G
    Laupacis, A
    GASTROENTEROLOGY, 1999, 116 (04) : A1204 - A1204
  • [12] Cost-effectiveness of preventive aspirin use and intensive downstaging polypectomy in patients with familial adenomatous polyposis: A microsimulation modeling study
    Saito, Eiko
    Mutoh, Michihiro
    Ishikawa, Hideki
    Kamo, Kenichi
    Fukui, Keisuke
    Hori, Megumi
    Ito, Yuri
    Chen, Yichi
    Sigel, Byron
    Sekiguchi, Masau
    Hemmi, Osamu
    Katanoda, Kota
    CANCER MEDICINE, 2023, 12 (18): : 19137 - 19148
  • [13] Cost-effectiveness of Tocilizumab in Switzerland: A Microsimulation Approach
    Wieser, S.
    Bruehlmann, P.
    Kyburz, D.
    Plessow, R.
    Pletscher, M.
    Diamantopoulos, A.
    Bruegger, U.
    SWISS MEDICAL WEEKLY, 2010, 140 : 9S - 9S
  • [14] Cost-Effectiveness of Adaptive Schedules for Lung Cancer Screening: A Modeling Study
    Cao, P.
    Jeon, J.
    Meza, R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S466 - S467
  • [15] Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis
    Goossens, Nicolas
    Singal, Amit G.
    King, Lindsay Y.
    Andersson, Karin L.
    Fuchs, Bryan C.
    Besa, Cecilia
    Taouli, Bachir
    Chung, Raymond T.
    Hoshida, Yujin
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2017, 8
  • [16] Cost-Effectiveness of a Biomarker-Based Screening Strategy for Hepatocellular Carcinoma in Patients with Cirrhosis
    Singal, Amit G.
    Chhatwal, Jagpreet
    Parikh, Neehar
    Tapper, Elliot
    LIVER CANCER, 2024, 13 (06) : 643 - 654
  • [17] Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C
    Lin, OS
    Keeffe, EB
    Sanders, GD
    Owens, DK
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (11) : 1159 - 1172
  • [18] COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING PROGRAM IN CHINA
    Zhou, D.
    Liu, Z.
    Wang, W.
    Zhao, M.
    Tang, W.
    Gong, F.
    VALUE IN HEALTH, 2022, 25 (07) : S377 - S377
  • [19] Cost-effectiveness of a breast cancer screening program in Switzerland
    Salvi, I.
    BREAST, 2025, 80
  • [20] Cost-effectiveness of the Norwegian breast cancer screening program
    van Luijt, P. A.
    Heijnsdijk, E. A. M.
    de Koning, H. J.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (04) : 833 - 840